Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program ...
Tenpoint Therapeutics, Ltd., a global, commercial-stage ophthalmic pharmaceutical company focused on developing ...
Yuvezzi is designed to achieve miosis 30 minutes after one drop for up to 10 hours. The eye drop is available through ...
LONDON--(BUSINESS WIRE)--Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tenpoint Therapeutics has launched with a $70 million ...
Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program to Make Novel Presbyopia Therapy More Accessible and Affordable Tenpoint Therapeutics, a leading ophthalmic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results